Bacteroides fragilis, a normal component of the human gut microbiota, has been shown to drive the differentiation of IL-10-secreting Treg cells by signaling through its capsular polysaccharide A, a TLR2 agonist [38]; B. fragilis has also been shown to protect mice from Helicobacter hepaticus infection and trinitrobenzene sulfonic acid (TNBS) induced

colitis [38, 47]. The two mechanisms described in the previous sentence restrict the host response to commensals, probably contributing to their peaceful and symbiotic cohabitation with the host. Among Paclitaxel concentration species with the ability to augment the mucosal immune response are the segmented filamentous bacteria (SFB). SFB are an unculturable bacterial species that is present in the mouse ileum

at weaning, and stimulates the postnatal maturation of mucosal immune responses in the mouse gut [48]. In the absence of SFB, mice have been shown to have lower IgA titers, low levels of mucosal Th1 cells and particularly Th17 cells, and have poor responses to intestinal pathogens, such as Citrobacter rodentium and Salmonella spp., suggesting that barrier function is maintained by microbiota-induced immune response [49-51]. The skin harbors a highly variable microbiota with distinct topographical niches [52]. Unlike in the gut, skin commensals are not required for development of the associated lymphoid PLX4032 nmr tissue, but they are required in order to maintain, through the production Idoxuridine of IL-1α, a sustained activation of Th1 cells and Th17 cells in the derma, and allow a protective immune response to skin pathogens, such as Leishmania major [53]. Monoassociation of the skin of GF mice with a single component of the skin microbiota of healthy skin, Staphylococcus epidermis, has been shown to be sufficient to reestablish the level of Th1- and Th17-cell activation observed in conventional mice, as well as confer resistance to L. major

skin infection [53]. The oral cavity also presents a number of very different niches hosting a great variety of microorganisms that often form biofilms, a rarity in other organs [54]. The oral microbiota has been shown to have roles in modulating local immunity, responding to infection, and contributing to local tissue pathology [55, 56]. Other barrier epithelia, such as those of the lungs and the vaginal mucosa, have also been shown to host a typical and abundant commensal microbiota and it is likely that in each tissue the commensals maintain a symbiosis with the host that contributes to the local immune homeostasis (reviewed in [57]).

In the recent year, timing for initiation of dialysis in advance CKD patients has been discussed widely, and there is a trend of not to dialysis patient solely depends LDK378 on the level of GFR or serum creatinine. If patients have no life-threatening condition or without major uremic symptom/sign, it is suggested dialysis could be delayed. In Taiwan, it has been a rule to initiate dialysis at a very low level of GFR, no matter due to Insurance regulation or patient’s willing. Our unique experience in dialysis initiation could provide more information for other countries. LIEW ADRIAN Department of Renal Medicine,

Tan Tock Seng Hospital, Singapore As a renal replacement therapy, renal transplantation confers the best survival advantage over dialysis for the patient with end-stage renal disease (ESRD)1. The transplantation of these patients prior to the initiation of dialysis therapy, known widely as preemptive renal transplantation, offers the advantage of avoiding the complications, morbidities, and infrastructure and manpower

costs associated with dialysis access and therapy. The further argument for preemptive transplantation stems Selumetinib in vivo from the unfavorable death rates among waitlisted patients compared with transplant recipients2. Indeed, large analyses of registry data, albeit retrospective in nature, had demonstrated that preemptive renal transplantation leads to considerable improvements in allograft and patient survival2,3, when compared to transplantation after a period of dialysis therapy. In fact, with incremental time on dialysis, the risk of graft loss and patient death after transplantation had been shown to increase linearly4. While the exact reasons for these improved outcomes with preemptive renal transplantation had not been clear, several observations had been made that could provide some information towards the contributing factors. Delayed graft function and biopsy-confirmed acute Enzalutamide research buy rejection are well known to have negative effects on graft survival, and the association of preemptive transplantation with

lower rates of these occurrences5 could contribute to its superior outcomes noted in these large analyses. The low solute clearances associated with dialysis therapy expose patients to risks of accelerated atherosclerosis, malnutrition and chronic inflammation, which are adverse outcomes that can be avoided with preemptive transplantation5. Preemptive transplant recipients have also been found to have socioeconomic and demographic features that predict better outcomes, namely younger age, higher educational background, economic viability and fewer HLA antigen mismatches3,6. Furthermore, it had also been implied that preemptive transplantation alone could have direct beneficial effects on graft survival. The precise timing to proceed with preemptive transplantation remains controversial.

Very interesting data published by Man et al. [22] suggest that IRF4 contributes to effector CD8+ T-cell differentiation by regulating metabolic pathways, in particular glycolysis. T cells need high energy supply for their strong proliferative burst after activation. To meet this demand, they switch their metabolism from oxidative phosphorylation to aerobic glycolysis [72]. This process seems to be greatly impaired in the absence of IRF4,

because activated Irf4–/– CD8+ T cells demonstrated lower uptake of glucose and produced less l-lactate as compared STA-9090 to WT CD8+ T cells. Moreover, oxygen consumption and extracellular acidification rate were lower in Irf4–/– as compared to WT CD8+ T cells. Consistently, the authors found direct binding of IRF4 to regulatory regions of genes encoding transcription factors that regulate cellular metabolism, including hypoxia-inducible factor α (HIF1α) and forkhead box O 1 (FOXO1), as well as of several genes encoding regulators of glycolysis such as the glucose transporters GLUT1 and GLUT3 [22]. However, it is still possible that the disturbed metabolic switch in Irf4–/–CD8+ T cells is secondary to their impaired expansion and effector differentiation, which is regulated by IRF4 by other means. Therefore, these attractive data need further evaluation, including

identification of the mechanisms through which IRF4 integrates strength of TCR ligation and metabolic pathways. Besides its requirement for effector CTL differentiation, IRF4 also participates in the formation of the memory Lenvatinib research buy CD8+ T-cell pool. In L. monocytogenes infected Irf4–/– mice, the numbers of antigen-specific memory CD8+ T cells and the production of the cytokines IFN-γ and TNF-α were significantly lower than those observed in L. monocytogenes infected WT mice [23]. Similarly in response to influenza Terminal deoxynucleotidyl transferase infection, mice with conditional deletion of IRF4 in CD8+ T cells generated significantly lower numbers of antigen-specific memory cells [25]. Taken together, IRF4 is a fundamental regulator of effector and memory CTL formation by acting upstream of other transcription factors, including BLIMP-1 and T-BET (Fig. 2),

which regulate these processes, and by connecting the strength of TCR ligation to aerobic glycolysis. Similarly to Th9 cells, Tc9 cells produce the cytokines IL-9 and IL-10 upon in vitro induction, whereas expression of the Th2-cytokines IL-5 and IL-13 is strongly reduced as compared to Tc2 cells. In comparison to CTLs, Tc9 cells express diminished amounts of the transcription factors EOMES and T-BET and, accordingly, they display low cytotoxic activity in vitro [63, 68]. In adoptive T-cell transfer experiments, Tc9 cells showed IL-9-dependent antitumor activity [68]. In an allergic airway disease model, Tc9 cells alone were not pathogenic by themselves, but promoted airway inflammation when combined with Th2 cells [63].

58 Although kDCs are capable of cytotoxic function, their differentiation into a killer phenotype is largely dependent on the presence of stimulatory factors

such as lipopolysaccharide, IL-15, IFN-α or IFN-γ,59,60 which were not used in any of our cytotoxic functional studies using enriched CD8α− and CD8α+ NK cells (Fig. 5c,e). Given this, we believe that the capacity of CD8α− NK cells to mediate modest (albeit significant) cytotoxic function is in direct correlation Dabrafenib to their activation profile and expression of cytotoxic proteins, and not to the potential acquisition of a killer phenotype by mDCs. Evaluation of PBMCs from SIV-infected macaques for CD8α− NK cells showed that these cells, and their CD16/CD56 subpopulations, are present at frequencies similar to those in naive animals (Fig. 7a,c). On the other hand, we detected a significant decrease in the frequency of CD8α+ CD16+ NK cells, which was accompanied by a significant increase

in the proportion of CD8α+ CD56− CD16− NK cells (Fig. 7b). Interestingly, when comparing CD16/CD56 subpopulations within CD8α− NK cells of naive and SIV-infected macaques, we also observed a decrease in the proportion of CD8α− CD16+ cells Z-VAD-FMK and a concomitant rise in the proportion of CD8α− CD56− CD16− NK cells, although these changes did not reach statistical significance (Fig. 7c). This observation suggests that during SIV infection, loss of CD3− CD16+ cells affects both CD8α− and CD8α+ NK cell subsets. Our results are in line with previous descriptions of HIV patients, where CD3− CD8+ CD16+ NK cells are depleted despite an overall increase in CD8+ lymphocytes.61,62 The ability of CD8α− NK cells to mediate ADCC activity during adaptive immune responses when anti-viral antibodies are Nintedanib (BIBF 1120) present, could contribute significantly to disease prevention and control.19,21,24 Stratov et al.63 have shown that robust ADCC responses, targeted mainly towards the Env protein, are observed in HIV-infected subjects. Importantly,

the effector cells identified were of the CD3− CD4− CD8− CD14− CD2+ CD56+/− phenotype, which is strikingly similar to the phenotype we describe here for macaque CD8α− NK cells. Despite the significant presence of mDCs in the CD8α− NK cell gate, our results are in line with those reported by Rutjens et al.34 and Reeves et al.,40 and confirm the presence and functional capacity of a CD8α− NK cell population in rhesus macaque PBMCs. Natural killer cells express a wide variety of chemokine receptors and tissue-homing molecules that influence their tissue distribution and migratory potential.29 Chronic SIV infection has been shown to enhance the expression of the gut-homing marker α4/β7 in different subsets of NK cells.47 It will be of interest to analyse the chemokine-receptor and tissue-homing molecule expression profiles of this novel subpopulation of circulatory CD8α− NK cells in naive and SIV-infected macaques.

The study was approved by local Ethics Committees and informed consent was obtained from the donors. In the following sections references

are given to papers which have used the same samples for other purposes. A recombinant fragment of MASP-1 comprising the CCP1-CCP2-SP domains (rCCP1-CCP2-SP) was produced in Escherichia coli, and refolded and purified as described previously [13]. A synthetic peptide representing the 15 C-terminal amino acid residues of human MASP-1 (CHHNKDWIQRVTGVR) was coupled to keyhole limpet haemocyanin. Three Wistar rats were immunized four times subcutaneously with 10 µg of this conjugate, emulsified first in complete Freund’s adjuvant and then in incomplete Freund’s adjuvant for boosts. Sera from the animals were tested for reactivity towards GPCR Compound Library purchase rCCP1-CCP2-SP coated onto microtitre wells. All rats responded and the rat with the highest titre was selected. IgG was purified from the anti-serum by affinity chromatography on Protein G-coupled beads. The serum was diluted 1/1 in phosphate-buffered saline (PBS; 137 mM NaCl, 2·7 mM KCl, 1·5 mM KH2PO4, 8·1 mM Na2HPO4, pH 7·4) Trichostatin A mw containing 10 mM EDTA (PBS/EDTA), and passed through the beads. After washing, the

bound IgG was eluted with 0·1 M glycine, pH 2·4. The immunoglobulin concentration was determined by spectroscopy at 280 nm. The purified IgG was biotinylated by standard procedure [26] using 167 µg biotin-N-hydroxysuccinimide ester (Sigma-Aldrich, Sitaxentan St Louis, MO, USA) per mg antibody. The anti-MASP-1 anti-serum was tested by Western blotting. MBL/MASP complexes were purified from serum by affinity chromatography on mannan coupled to Sepharose beads, as described previously [8]. The complexes, as well as a preparation of rCCP1-CCP2-SP, were separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) in non-reducing conditions followed by blotting onto a membrane. For the preparation of Western blotting strips, MBL/MASP

complexes corresponding to 30 µg MBL were loaded onto a single-well XT-Criterion pre-cast 4–12% gradient Bis-Tris polyacrylamide gel (Bio-Rad, Copenhagen, Denmark) and cut into 2·5-mm-wide strips after blotting, resulting in approximately 1 µg MBL (+ associated proteins) per strip. The proteins were blotted onto a nitrocellulose membrane (Hybond-ECN; GE Healthcare, Hilleroed, Denmark) in transfer buffer (25 mM Tris, 0·192 M glycine, 20% v/v ethanol, 0·1% w/v SDS, pH 8·3) for 500 volt-hours. The membrane was blocked in 0·1% Tween 20 in Tris-buffered saline (TBS) (10 mM Tris–HCl, 140 mM NaCl, 1·5 mM NaN3, pH 7·4) before being cut into strips. The strips were incubated with primary antibodies (normal rat IgG or rat anti-MASP-1 antibody) diluted in primary buffer (TBS with 0·05% Tween 20 (TBS/Tw), 1 mM EDTA, with 1 mg human serum albumin (HAS) and 100 µg normal human IgG (hIgG) added per ml) in eight-well trays (Octaline, Pateof, Denmark) for 2·5 h on a rocking table.

Methods: 72 pre-dialysis patients were enrolled from a single medical center. Serum biochemistry data and p-cresyl sulfate were measured. The clinical outcomes including cardiovascular event, all-cause mortality and dialysis event were recorded during a 3 years follow-up. Results: After adjusting other independent variables, multivariate Cox regression analysis showed age (HR:1.12, p = 0.01), cardiovascular disease history (HR:6.28, p = 0.02) and PCS (HR:1.12, p = 0.02) were independently associated with cardiovascular event; age (HR:0.91,

p < 0.01), serum albumin (HR:0.03, p < 0.01) Alectinib order and PCS level (HR:1.17, p < 0.01) reached significant correlation with dialysis event. Kaplan–Meier analysis revealed that patients with higher serum p-cresyl sulfate (>6 mg/L) was significantly associated with cardiovascular and dialysis event selleck inhibitor (Log rank p = 0.03, Log rank p < 0.01, respectively). Conclusion: Our study shows serum PCS could be a useful marker to predict cardiovascular event and renal function progression in CKD patients without dialysis. WATATANI HIROYUKI1, MAESHIMA YOHEI2, HINAMOTO NORIKAZU1, UJIKE HARUYO1, TANABE KATSUYUKI1, MASUDA KANA1, SUGIYAMA HITOSHI3, SAKAI YOSHIKI4, MAKINO HIROFUMI1 1Dept. of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; 2Dept. of Chronic Kidney Disease and Cardiovascular disease, Okayama Univ. Graduate School

of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; 3Center for Chronic Kidney Disease and Peritoneal Dialysis, Okayama Univ. Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; 4ONO Pharmaceutical Co., Ltd., Osaka, Japan Montelukast Sodium Introduction: Cardiovascular disease is a leading cause of mortality in patients with CKD, and vascular calcification serves as a key modifier of disease progression. ONO-1301 (ONO) is a novel sustained-release prostacyclin analog possessing thromboxane (TX) synthase inhibitory activity. We recently reported the renoprotective effects of ONO in experimental models of diabetic

nephropathy and obstructive uropathy. In the present study, we aimed to investigate the therapeutic efficacies of ONO on progressive CKD and vascular calcification in a rat model of adenine-induced CKD. Methods: Male Sprague-Dawley rats at 13 weeks of age were fed with the diet containing either 0.75% (CKD) or 0% (control) adenine along with 2.5% protein. After 3 weeks, serum creatinine levels were measured and animals were divided into one of two treatment groups with equivalent kidney dysfunction. For the following 5 weeks, animals were fed with standard rat chow, and ONO (6 mg/kg/day) or vehicle buffer was orally administered. Urine, serum, kidneys and thoracic aorta were obtained and subjected to evaluation. Results: Treatment with ONO did not significantly improve adenine-induced renal functional deterioration (BUN and S-Cr) and renal histological alterations.

[44] On the other hand, very aggressive EAE induction (for example, repeated immunization with high dosages of heat-killed Mtb) completely abrogates IFN-β efficacy NVP-LDE225 supplier in wild-type mice (Inoue et al., unpublished data). Hence, EAE induced by moderately aggressive immunization may develop as a mixture of two EAE subtypes; NLRP3 inflammasome-dependent and -independent. When two subtypes of EAE are ongoing, it may be possible that IFN-β efficacy correlates with levels

of NLRP3 inflammasome dependency in EAE development. Although two subtypes of EAE may be occurring simultaneously within some of the disease in WT mice, the findings are summarized as follows: NLRP3 inflammasome-dependent EAE is a disease that responds to IFN-β treatment, whereas NLRP3 inflammasome-independent EAE is a disease that is resistant to IFN-β (Fig. 2). Previous studies have shown that passive EAE induced by Th17 cell transfer is resistant to IFN-β treatment, whereas the disease induced by Th1 cells responds to IFN-β treatment.[81] The result is counterintuitive because IFN-β inhibits Th17 responses;[62, 65] and it will be of great interest to understand why Th17-mediated EAE cannot be treated by IFN-β. Activation status of the NLRP3 inflammasome is not known in the Th17-mediated EAE model, but the result (resistance of Th17-mediated passive EAE to IFN-β) does not conflict with IFN-β resistance in NLRP3 inflammasome-independent

EAE. This is because the Th17 response itself is not the reason

for NLRP3 inflammasome-dependent EAE progression.[44] Further studies will be necessary to determine whether or not these two types CCI-779 cell line of IFN-β-resistant EAE (Th17-type EAE and NLRP3 inflammasome-independent C1GALT1 EAE) share the same mechanism. It is currently unknown whether NLRP3 inflammasome-independent MS exists. It is also not known what type of event is an equivalent of ‘aggressive immunization’ in MS. However, if the current findings on the correlation between NLRP3 inflammasome activation and response to IFN-β in EAE can be applied to MS, it might be possible to predict MS patients who do not respond well to IFN-β therapy. For example, the activation status of the NLRP3 inflammasome might be a prediction marker. Or, it might be possible to identify prediction markers by screening molecules that show altered expression in NLRP3 inflammasome-independent EAE. It is also possible to test such molecules for prognosis markers, or even as molecular targets of selected treatment(s). “
“Human Vγ9Vδ2 T cells play a crucial role in early immune response to intracellular pathogens. Their number is drastically increased in the peripheral blood of patients during the acute phase of brucellosis. In vitro, Vγ9Vδ2 T cells exhibit strong cytolytic activity against Brucella-infected cells and impair intracellular growth of Brucella suis in autologous macrophages.

Onishi et al. [74], detected the genetic polymorphism of TNF-α (α1, α2) and TNF-β (β1, β2). All patients having TNF-β1/1 homozygote were alive, and a significantly favourable prognosis in the patients with TNF-β1/1 homozygote compared with other TNF-β polymorphism was observed. In the Turkish population, rs1800629 polymorphism is associated with an increased risk of hepatocellular carcinoma

as this polymorphism plays role in the regulation of expression level. A case–control study selleck kinase inhibitor was designed by Akkiz et al. [75], and they found that rs1800629 genotype was significantly associated with the risk of HCC. The presence of the high producer allele rs1800629 A in the TNF-α gene was associated with an increased risk of the development of HCC in Turkish population. Acute pancreatitis.  Tumour necrosis factor α (TNFα) plays important roles

in the pathogenesis of acute pancreatitis (AP). Ozhan et al. [76] determined two TNF promoter polymorphisms (rs1800629 and rs361525) in patients with AP and healthy controls. The frequencies of these polymorphisms were similar in both patients with mild or severe pancreatitis and in controls. Sarcoidosis is a complex disease with autoimmune basis, a multisystemic granulomatous disorder which occurs in almost all populations. Disease manifestations are localized to lung and skin, but the involvement of other parts such as eyes, lymph nodes, parotid glands, heart, liver and spleen can also occur. Sharma et al. [25] reported for the first

time the association of TNF haplotypes and genotypes with sarcoidosis and its prognosis in the Indian population. EPZ6438 Five promoter polymorphism in the TNF-α gene mafosfamide and one in LTα gene (rs909253) were genotyped in North Indian patients. They have measured sTNF-α and serum angiotensin–converting enzyme (SACE) levels. Serum TNF-alpha and SACE levels are influenced by rs1800629 and rs361525 polymorphisms. The patients and controls have significant differences in haplotype frequencies. The haplotype GTCCGG was identified as the major risk/susceptibility haplotype and was associated with increased SACE levels in the patients. Cystic fibrosis conductance regulator, tumour necrosis factor, interferon-alpha-10, interferon-alpha-17 and interferon-gamma genotyping as potential risk markers in pulmonary sarcoidosis pathogenesis were detected by Makrythanasis et al. [77], in Greek patients. They have detected a statistically significant increase of CFTR mutation carriers in patients with sarcoidosis than in the control population. A difference was observed within sarcoidosis patients group where patients with CFTR mutations suffered more frequently from dyspnoea than those without. Tumour necrosis factor (TNF-α), a proinflammatory cytokine, plays an important role in multiple sclerosis (MS) pathogenesis. In Turkish population, Akcali et al.

Written consent given and documented regarding treatment option to be pursued. □ Done □ Not done       “
“Aim:  To investigate whether gut bacteria translocation occurs in end-stage renal disease patients and contributes to microinflammation in end-stage renal disease (ESRD). Methods:  The subjects were divided into two groups: nondialysed ESRD patients (n = 30) and healthy controls (n = 10). Blood samples from all participants were subjected to

bacterial 16S ribosomal DNA amplification Galunisertib cost and DNA pyrosequencing to determine the presence of bacteria, and the alteration of gut microbiomes were examined with the same methods. High-sensitive C-reactive protein and interleukin-6 were detected. Plasma D-lactate was tested for gut permeability. Results:  Bacterial DNAs were detected in the blood of 20% (6/30) of the ESRD patients. All the observed genera in blood (Klebsiella spp, Proteus spp, Escherichia spp, Enterobacter Alectinib datasheet spp, and Pseudomonas spp) were overgrown

in the guts of the ESRD patients. Plasma D-lactate, High-sensitive C-reactive protein, and interleukin-6 levels were significantly higher in patients with bacterial DNA than those without. The control group showed the same results as that of patients without bacterial DNA. Conclusion:  Bacterial translocation occurs in ESRD patients and is associated with microinflammation in end stage renal disease. “
“Aim:  To further reveal the effects of leflunomide on renal protection and on inflammatory response using streptozotocin (STZ) induced diabetic rats. Methods:  Male Wistar rats were randomly divided into normal control group (NC), diabetic group (DM) and leflunomide N-acetylglucosamine-1-phosphate transferase treatment group (LEF). LEF group rats were given leflunomide (5 mg/kg)

once daily. At the end of the 12th week, general biochemical parameters in three groups were determined. The renal histopathology was observed by light microscopy and electron microscopy. Further biochemical analysis of the gene and protein expression of nuclear factor kappa B (NF-κB), tumour necrosis factor-alpha (TNF-α), monocyte chemoattractant protein-1 (MCP-1) and ED-1 positive cells in renal tissue were provided using real-time reverse transcription-polymerase chain reaction and immunohistochemistry. Results:  Compared with NC group rats, systolic blood pressure, blood glucose (BG), glycohemoglobin (HbAlc), renal hypertrophy index, urine albumin excretion rate (AER) and serum creatinine were increased in DM group rats (P < 0.05). Treatment with leflunomide can improve these parameters except systolic blood pressure, BG and HbAlc. Creatinine clearance rate (Ccr) in the DM group was significantly lower than that of the NC group, and leflunomide can increase its level. Compared with DM group rats, the pathological damages were significantly relieved in LEF group rats.

It is highly PS 341 satisfying that the Congress format of master lectures, theme-based symposia and oral workshop sessions were much appreciated. The meeting witnessed a full house attendance on all three days, thanks to the participation of a large number of young and enthusiastic scientists. The inclusion of (i) Ten Best Oral Presentations session, (ii) round table discussion on gender equality issues and (iii) the concept of ePoster viewing (Fig. 3) turned out to be the three major highlights of the meeting. “
“RD15 is a genomic region of difference (RD) present in Mycobacterium

tuberculosis H37Rv but absent in all strains of Mycobacterium bovis BCG. RD15 contains genes encoding proteins of mammalian cell entry (Mce3A-F), important for the invasion and survival of M. tuberculosis in host cells. In

this study, we have evaluated cellular immune responses to RD15 proteins using peripheral blood mononuclear cells (PBMC) from pulmonary tuberculosis patients and M. bovis BCG-vaccinated healthy subjects. PBMC were tested for T-helper (Th) type 1 [antigen-induced Crizotinib proliferation and interferon (IFN)-γ secretion] and anti-inflammatory [interleukin (IL)-10 secretion] responses to complex mycobacterial antigens and peptides corresponding to proteins of RD1 and RD15. In Th1 assays, complex mycobacterial antigens Adenosine triphosphate induced strong responses in both donor groups, and RD1 induced strong responses in tuberculosis patients and moderate responses in healthy subjects, whereas RD15 induced weak responses in tuberculosis patients and strong to moderate responses in healthy subjects. IL-10 secretion in both donor groups was strong to moderate in response to complex mycobacterial antigens, but weak in response to RD1 and RD15. Analysis of IFN-γ : IL-10 ratios showed strong Th1 biases to complex mycobacterial antigens and RD1 in both donor groups, and to RD15 and RD1504 (Mce3A) in healthy subjects

only. These results suggest that RD1504 is the best Th1-stimulating antigen present in RD15, and therefore may be a potential vaccine candidate against TB. Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), is estimated to infect one-third of the world’s population, and causes active disease in about 9.3 million people per year, with nearly 1.8 million deaths (WHO Report, 2009). The global control of TB requires specific diagnostic reagent(s) and effective vaccine(s) capable of protection in all parts of the world against all forms of the disease (Smith, 2009). The only available vaccine for use against TB is the bacillus Calmette–Guerin (BCG), a live attenuated strain of the virulent bovine tubercle bacillus Mycobacterium bovis.